Codexis (NASDAQ:CDXS) reported first-quarter 2026 revenue of $15.2 million, up from $7.5 million a year earlier, as the company highlighted continued progress commercializing its ECO Synthesis enzymatic manufacturing platform for RNA medicines and ...

Q1 2026 Management view Dr. Alison Moore said the company “accomplished a lot” since the prior call and plans to present “important new data on our ECO Synthesis technology” at the TIDES Conference, positioning ECO Synthesis as an enzymatic manufacturing platform for siRNA as pipelines broaden and scale

As RNAi therapies expand into larger indications, manufacturing scalability, maintaining process control and delivering high-quality product is critical. Codexis will present data demonstrating advances in controlling phosphorothioate stereochemistry,

Guidance holds steady: Management kept its 2026 revenue target at $72–$76 million, expecting stronger results in the second half. Scaling ambitions: A 0.5 kilogram ECO Synthesis siRNA production scale is planned by year-end, with ongoing process optimization

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices ...

Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, today announced that it will report its financial results for the first quarter of 2026 on Thursday,

As of Sept. 30, institutional investors held over 86% of the outstanding shares. These include big names like BlackRock, Vanguard, and Fidelity as well as healthcare specialist funds including Vivo Ventures and Opaleye Management. Codexis created a ...

Codexis CDXS will release its quarterly earnings report on Wednesday, 2025-08-13. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Codexis to report an earnings per share (EPS) of $-0.16. Investors in Codexis are eagerly ...

AI gets playful: OpenAI launched Codex Pets, animated companions that display coding task updates and allow lightweight interaction with its Codex tool. Biotech targets scale: Codexis reaffirmed 2026 revenue guidance and revealed new stereochemistry ...